Assessment and management of retinopathy of prematurity in the era of anti-vascular endothelial growth factor (VEGF)
ASH Tsai, HD Chou, XC Ling, T Al-Khaled… - Progress in retinal and …, 2022 - Elsevier
The incidence of retinopathy of prematurity (ROP) continues to rise due to the improved
survival of very low birth weight infants in developed countries. This epidemic is also fueled …
survival of very low birth weight infants in developed countries. This epidemic is also fueled …
[HTML][HTML] Retinopathy of prematurity and neurodevelopmental outcomes in preterm infants: A systematic review and meta-analysis
S Diggikar, P Gurumoorthy, P Trif, D Mudura… - Frontiers in …, 2023 - frontiersin.org
Background Retinopathy of prematurity (ROP) and abnormal brain development share
similar risk factors and mechanisms. There has been contrasting evidence on the …
similar risk factors and mechanisms. There has been contrasting evidence on the …
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled …
A Stahl, D Lepore, A Fielder, B Fleck, JD Reynolds… - The Lancet, 2019 - thelancet.com
Background Despite increasing worldwide use of anti-vascular endothelial growth factor
agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular …
agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular …
2-year outcomes of ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW extension study) …
N Marlow, A Stahl, D Lepore, A Fielder… - The Lancet Child & …, 2021 - thelancet.com
Background Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors is
increasingly used to treat retinopathy of prematurity (ROP) in the absence of evidence about …
increasingly used to treat retinopathy of prematurity (ROP) in the absence of evidence about …
Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis
M Kaushal, A Razak, W Patel, AK Pullattayil… - Journal of …, 2021 - nature.com
Objective To systematically review the studies exploring the association between
bevacizumab and neurodevelopmental outcomes. Methods Embase, Medline, CINAHL, and …
bevacizumab and neurodevelopmental outcomes. Methods Embase, Medline, CINAHL, and …
Neurodevelopmental outcomes after intravitreal bevacizumab therapy for retinopathy of prematurity: a prospective case-control study
YY Fan, YS Huang, CY Huang, JF Hsu, CP Shih… - Ophthalmology, 2019 - Elsevier
Purpose To evaluate the neurodevelopmental and ocular developmental outcomes in
premature children who have undergone intravitreal bevacizumab injection (IVB) for …
premature children who have undergone intravitreal bevacizumab injection (IVB) for …
Strategies to prevent severe retinopathy of prematurity: a 2020 update and meta-analysis
TS Raghuveer, R Zackula - Neoreviews, 2020 - publications.aap.org
The incidence of retinopathy of prematurity (ROP) is showing an increasing trend in the
United States. This may be because of increasing survival rates among extremely preterm …
United States. This may be because of increasing survival rates among extremely preterm …
Assessment of retinopathy of prematurity regression and reactivation using an artificial intelligence–based vascular severity score
SK Eilts, JM Pfeil, B Poschkamp, TU Krohne… - JAMA Network …, 2023 - jamanetwork.com
Importance One of the biggest challenges when using anti–vascular endothelial growth
factor (VEGF) agents to treat retinopathy of prematurity (ROP) is the need to perform long …
factor (VEGF) agents to treat retinopathy of prematurity (ROP) is the need to perform long …
Neurodevelopmental outcomes after bevacizumab treatment for retinopathy of prematurity: a meta-analysis
Purpose To evaluate neurodevelopmental outcomes after intravitreal bevacizumab (IVB)
therapy in retinopathy of prematurity (ROP) infants compared with those not exposed to IVB …
therapy in retinopathy of prematurity (ROP) infants compared with those not exposed to IVB …
Ranibizumab in retinopathy of prematurity–one‐year follow‐up of ophthalmic outcomes and two‐year follow‐up of neurodevelopmental outcomes from the CARE …
A Stahl, MC Bründer, WA Lagrèze… - Acta …, 2022 - Wiley Online Library
Purpose The primary endpoint results from the comparing alternative ranibizumab dosages
for safety and efficacy in retinopathy of prematurity (CARE‐ROP) core study identified …
for safety and efficacy in retinopathy of prematurity (CARE‐ROP) core study identified …